Application of massively parallel sequencing (MPS) for clinical analyses: challenges and opportunities.
1Immunology, Genetics and Pathology, IGP, Uppsala Universitet, Uppsala, Sweden
The development of methods for ultra-high throughput DNA sequencing using massively parallel read technologies have revolutionized many field fields of biology and medicine, and are beginning to be accepted also for routine clinical analyses. It is clear that MPS is becoming the primary method of choice for a whole range of clinical analyses, and is likely to replace many of the existing methods for nucleic acid analyses. However, the wide diversity of technology platforms for sequencing, differing in throughput, accuracy and cost, and the very rapid turn-over of technologies provides particular challenges for clinical use. In this presentation will provide an overview of different technology platforms and illustrate the opportunities and challenges provided by these.